Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
175 hedge funds and large institutions have $819M invested in Verve Therapeutics in 2025 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 50 increasing their positions, 68 reducing their positions, and 57 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
122% more capital invested
Capital invested by funds: $369M → $819M (+$450M)
8% less funds holding
Funds holding: 191 → 175 (-16)
9.11% less ownership
Funds ownership: 90.95% → 81.84% (-9.1%)
25% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 57
26% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 68
86% less call options, than puts
Call options by funds: $5.84M | Put options by funds: $41.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$38.3M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$15.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.4M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$9.96M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$31.6M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$15.7M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$13.7M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$12.6M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$11.4M |
VERV Hedge Fund Activity: Q2 2025 in Review
175 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2025, worth a combined $819M — up 122% from $369M a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of VERV and 43 opened new positions — a net loss of 14 holders — while 68 trimmed existing stakes and 50 added.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $38.3M. The largest seller was BVF Inc, exiting entirely with an estimated $31.6M sold.
- 175 institutional investors held Verve Therapeutics (VERV) as of Q2 2025, down from 191 in Q1 2025.
- Funds reported $819M of Verve Therapeutics stock for Q2 2025, up 122% quarter-over-quarter.
- 43 funds opened new Verve Therapeutics positions in Q2 2025 and 57 closed out, a net change of -14 holders.
- The largest Verve Therapeutics buyer in Q2 2025 was Pentwater Capital Management, an estimated $38.3M added.
- The largest Verve Therapeutics seller in Q2 2025 was BVF Inc, an estimated $31.6M sold.
Based on aggregated 13F filings for Q2 2025.